News related to
Rough Guide

Dubai has introduced the world’s first icon-based system to clearly signal whether content is crafted by humans, artificial intelligence, or a blend of both. Launched by Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, the Human–Machine Collaboration classification marks a shift in content disclosure standards. The initiative requires government entities to adopt the system immediately, marking a drive towards accountability and public trust in an era of rapid AI integration.

The HMC framework comprises five primary icons: All Human, Human-Led, Machine-Assisted, Machine-Led, and All Machine, each reflecting increasing levels of machine involvement. Developers can further specify nine functional icons to indicate AI contribution across tasks such as ideation, data analysis, writing, translation, visuals, and design.

The system, developed by the Dubai Future Foundation and endorsed by Sheikh Hamdan in his capacity as Chairman of its Board of Trustees, is compulsory for all Dubai government research and knowledge publications. Media content, academic papers, technical reports, videos, academic journals and other multimedia outputs must now prominently display the appropriate icons. For non-government creators, the icons are voluntary but available for ethical transparency.

Sheikh Hamdan said transparency is essential for distinguishing human creativity from machine efficacy. He urged global content creators—researchers, publishers, writers, and designers—to adopt the new classification as a norm. On LinkedIn, he stated: “Today, we launch the world’s first Human–Machine Collaboration Icons…a new global benchmark in the age of AI,” inviting worldwide adoption.

The initiative meets growing demands for clarity around AI-generated content in scientific, academic, and creative fields. As AI technologies such as generative models and automation tools proliferate, distinguishing authorship becomes increasingly complex. The HMC system addresses this by offering concise visual indicators of machine involvement throughout a document’s lifecycle.

Beyond classification, the icons offer practical guidelines. Each icon can appear on the cover, footer, or bibliography of a document, with no numerical thresholds assigned. The nine functional icons enable precise reporting by highlighting stages influenced by AI, such as data collection or translation. The system avoids quantification due to challenges in objectively assessing AI contribution levels.

Dubai’s icon strategy is modelled on enhancing trust in public knowledge creation. Government entities in Dubai must adopt the icons; private sector use is labelled “opt-in and voluntary,” encouraging transparency across broader sectors. The icons aim to build credibility in educational materials, annual reports, research briefs, social media content, public-facing campaigns, and design outputs.

Industry experts have broadly welcomed the initiative. Fast Company Middle East noted the dual-layer approach offers transparency without excessive complexity, while Economy Middle East reported Sheikh Hamdan’s emphasis on the blurred lines between human art and machine output. Gulf News cited the icons as a tool for “honest self-assessment,” reinforcing accountability among content creators.

Academics and publishers are now exploring integration possibilities. The system could become a template for journal submission protocols or university publishing frameworks. Concerns persist about compliance monitoring and the potential for misuse—some question whether creators may understate AI contribution or apply icons inconsistently across formats.

Dubai Future Foundation has emphasised that icons are free to use and do not require licensing; they are copyrighted but freely deployable, with no prior permission needed. The foundation’s intention is to encourage natural adoption in scholarly work, media, and social channels, promoting a culture of transparency rather than regulatory enforcement.

Global observers note that while Dubai is first, other cities and institutions are likely to follow. The HMC icons address growing demand from research communities for AI disclosure standards, amid debates over authorship attribution, peer review confidence, and reproducibility.

Dubai’s initiative closes a gap in ethical AI practice by establishing a clear visual code for machine involvement. As AI-generated content becomes ubiquitous, its success will depend on global uptake, consistent application, and alignment with existing ethics and publishing standards. In the meantime, Dubai’s icons offer a blueprint for transparency, setting a new bar for content creation in the AI era.

Dragon Oil’s board has named Abdulkarim Ahmed Al Maazmi as Acting Chief Executive Officer, entrusting him with steering the company’s strategic trajectory. With a career spanning more than four decades in the oil and gas sector, he succeeds Ali Rashid Al‑Jarwan—CEO since March 2017—in a leadership transition that signals continuity in the firm’s pursuit of global growth.

Al Maazmi joined Dragon Oil, a wholly owned subsidiary of Emirates National Oil Company, in May 2018 as Executive Director of Exploration & New Ventures, overseeing operations across the MENA region. Prior to that, his career included senior roles that shaped key upstream strategies, including serving as President and General Manager of BP UAE in July 2011. There he led partnerships with ADNOC and the Government of Sharjah and oversaw approximately 235,000 barrels per day of oil production.

Board members acknowledged Al Maazmi’s “high‑calibre leadership and strategic vision” as critical to guiding Dragon Oil’s established assets in Turkmenistan, Egypt and Iraq, as well as its commitment to operational excellence, safety and sustainability. The LinkedIn announcement highlights his appointment as “reflecting continued commitment to operational excellence, safety, sustainability, and expanding our global footprint in support of energy security and economic development”.

During his tenure, Al Maazmi steered major strategic projects. In Turkmenistan, he played a pivotal role in projects within the Cheleken Contract Area, consolidating Dragon Oil’s productive presence there since 2000. He also guided initiatives in Egypt’s Gulf of Suez through the GUPCO joint venture and advanced development in Iraq’s Block 9 in partnership with EGPC and KEC.

Stakeholder relations have also been a hallmark of his career. Between 2011 and 2016, Al Maazmi served on the boards of regional energy firms such as ADCO, ADMA, ADGAS, NGSCO and Bunduq Abu Dhabi, and contributed to governance at the Petroleum Institute and the Emirates National Development Program. His track record in negotiating concession renewals and delivering results in multicultural environments underlines his diplomatic and managerial prowess.

In his new leadership role, Al Maazmi inherits a portfolio that includes mature fields like those in Turkmenistan’s Caspian Sea, growth-led projects in the Gulf of Suez, and exploration ventures in Iraq. Observers anticipate his emphasis will include reinforcing localisation and succession planning—as promoted by the UAE government—while also aligning operations with global decarbonisation goals and emerging regional dynamics.

Colleagues report his approach blends technical depth with empowerment of multi‑disciplinary teams, underpinned by an accountability-focused mindset. This ethos was celebrated during a Dragon Oil town‑hall in July 2025 under the theme “One Team, One Vision”, where Al Maazmi emphasised collective effort in achieving strategic aims across Dubai headquarters and field sites.

Industry analysts view the appointment as timely. As upstream players adjust strategies amid evolving energy demand and geopolitical shifts, leadership continuity becomes a critical asset. Al Maazmi’s elevation reflects Dragon Oil’s desire to maintain momentum in long‑standing assets while exploring new areas of growth and innovative technologies.

His stewardship is also expected to further strengthen Dragon Oil’s ties with host governments. A meeting in late 2024 between Al Maazmi and Turkmenistan’s deputy prime minister reinforced state-level confidence in Dragon Oil’s capacity to deliver mutual benefits. Such relationships are vital as the company aims to balance production targets with evolving energy policies.

This leadership transition also aligns with ENOC’s broader strategy to position Dragon Oil as a national champion in upstream operations. As acting CEO, Al Maazmi is likely to champion projects that balance commercial returns with the UAE’s sustainability and security objectives, while also nurturing domestic talent through Emiratisation and professional development initiatives.

With over forty years in the industry and an extensive track record—from field production to corporate governance—Abdulkarim Al Maazmi emerges as a poised leader for Dragon Oil’s next chapter. His appointment signals a commitment to operational resilience, international collaboration and long‑term value creation in a sector grappling with transformation.

Abu Dhabi—The Central Bank of the UAE has revoked the licence of Al Khazna Insurance Company P. S. C under Article 33 of Federal Decree Law No. 48 of 2023 governing insurance activities, after the firm failed to meet mandatory licensing requirements during a suspension period.

The central bank’s investigations uncovered persistent non-compliance with both the Insurance Law and additional CBUAE regulations throughout the suspension, leading to decisive regulatory action. The move underscores the regulator’s commitment to maintaining the integrity and transparency of the UAE’s insurance sector and broader financial system.

Al Khazna, based in Abu Dhabi, saw its licence suspended earlier in line with provisions introduced under the 2023 law. As part of this suspension, insurers are required to resolve any compliance gaps before licence reinstatement. However, the CBUAE found that Al Khazna failed to correct these deficiencies during that period.

Regulatory scrutiny appears to have intensified since the Insurance Law came into effect, as authorities aim to bolster trust in financial markets. The central bank, acting through its supervisory mandate, has intensified examinations across insurance entities to ensure adherence to legal and regulatory standards.

Industry analysts note that the revocation itself does not automatically trigger an exit cascade, but it sends a stern warning. “Companies that fail to meet minimum capital, solvency or operational standards risk losing their licences outright,” said an insurance consultant based in Dubai. The loss of licence bars Al Khazna from conducting any further insurance operations in the UAE unless formally reinstated under strict new terms.

Under the Insurance Law, the CBUAE is mandated to revoke licences if, during suspension, firms fail to comply with corrective actions, including capital adequacy, governance, risk management and statutory reporting. The central bank’s review team reportedly flagged multiple gaps, though details of specific breaches have not been made public.

The CBUAE’s zero-tolerance approach signals broader regulatory tightening across financial services. Since March, the central bank has levied fines totaling over AED 2.6 million against certain insurance firms and banking institutions for breach of tax compliance, antimoney‑laundering and other framework violations.

Following Al Khazna’s licence revocation, policyholders may face claims uncertainty. The CBUAE has provided guidelines to insurers under licence suspension, recommending them to continue servicing in-force policies and settle outstanding claims under regulatory oversight. It is expected that the regulator will enforce a similar approach for Al Khazna to safeguard consumer interests. Discussions are reportedly underway with other operators to absorb liability where needed, according to industry insiders.

Market reaction has been muted so far. Shares of listed insurers remained steady, while privately held peers are reviewing their own compliance procedures. “This clearly demonstrates that regulatory grace periods must be matched with swift corrective action and transparency,” said the insurance consultant in Dubai.

Al Khazna joined a wave of sector-wide transformation last year when the Insurance Law was introduced. Designed to implement international best practices, the legislation set new capital thresholds, risk frameworks and governance structures for all insurers its jurisdiction. Experts say the law’s strict enforcement marks a seminal shift towards a more robust and risk-aware sector.

A spokesperson for the CBUAE emphasised that regulatory enforcement will continue. “The decision affirms our mandate to uphold the stability and integrity of the UAE’s financial system,” the spokesman said at a press briefing in Abu Dhabi. “All insurance firms must adhere fully to the legal and regulatory standards or face similar consequences.”

Al Khazna’s licence revocation now places it among a small but growing list of financial firms that have failed to align swiftly with enhanced regulatory norms. It remains unclear whether the firm will pursue a licence reinstatement by dissolving all compliance breaches or whether it will exit the market. Sources within the firm declined to provide comment on next steps.

Following Al Khazna’s licence revocation, the central bank may step up its inspection frequency across the sector. Regulators are expected to issue fresh guidance to insurers on enhancing risk management, capital planning and governance practices. Analysts believe this incident will encourage all players to accelerate internal audits and compliance enhancements.

The CBUAE has also emphasised its openness to collaboration. It continues to engage with industry stakeholders via working groups and technical committees to align regulatory expectations with market realities while protecting policyholders.

A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a chronic disease. The product, from Novo Nordisk, is licensed for adults and those aged 12 and above who are obese or overweight with at least one weight‑related condition such as hypertension, type 2 diabetes or dyslipidemia.

The drug works by mimicking the gut hormone GLP‑1, promoting a sense of fullness and reducing food intake when combined with healthier diet and exercise regimes. Its introduction follows approval by the Health Sciences Authority on 28 February 2025 for use among adolescents with obesity—a first in the region.

Over 600,000 adult Singaporeans are classified as obese, a figure that underlines the public health urgency given the hundreds of comorbidities associated with obesity. The rollout of Wegovy® offers a medically guided therapy for a condition too often dismissed as a lifestyle issue.

Clinical experts argue obesity stems from complex biological factors, ranging from genetics to hormonal imbalances. Dr Abel Soh, chair of the Endocrine and Metabolic Society of Singapore, says, “Obesity is not simply the result of lifestyle choices—it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones and environment”.

Approval comes amid global strain on semaglutide supplies. Local clinics previously stocked Ozempic and Rybelsus and faced intermittent shortages, with expectant Wegovy® shipments deferred until 2026 according to some medical guides. Private clinics were unable to reference branded drugs until local stock arrived, due to regulatory restrictions.

Available through prescription in private settings, Wegovy® will be offered alongside diet and exercise interventions. The injectable is indicated for chronic use; ongoing physician oversight is advised. Regulatory approval includes a requirement to review treatment after 12 weeks in adolescents if BMI reduction falls below 5% on the full 2.4 mg dose.

Globally, Wegovy® was first authorised in the US in June 2021, followed by EU approval in early 2022. Earlier, in Singapore, semaglutide received approval under Ozempic’s label starting March 2023 for diabetic therapy.

The drug’s effectiveness has been supported by the STEP clinical programmes, showing average weight reductions of between 10–15% over periods of 68 to 104 weeks. Benefits extend beyond weight loss to metabolic health improvements, including lower blood pressure and decreased cholesterol.

Local uptake may mirror global patterns, where appetite suppression and metabolic regulation paired with lifestyle changes have delivered sustainable weight loss without surgery. However, supply challenges persist: healthcare providers warn that stocks may remain tight, with some expect delays or patient referrals under the Ozempic brand.

Novo Nordisk has also updated its savings programme for Wegovy®, making it more accessible to cash‑paying patients. The initiative aims to reduce financial barriers, although uptake and cost‑effectiveness will depend on real‑world pricing and insurance coverage.